Is it Possible to Treat Osteosarcoma Using Oligonucleotides Confined into Controlled Release Drug Delivery Systems?

Author(s): Savas Topuk, Yener Akyuva, Numan Karaaslan, Cagri A. Mutlu, Ibrahim Yilmaz*, Mehmet Isyar, Duygu Yasar Sirin, Semih Akkaya, Hanefi Özbek, Mahir Mahirogullari.

Journal Name: Current Pharmaceutical Biotechnology

Volume 18 , Issue 6 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Purpose: The present study aimed to analyze the researches that are at the experimental phase concerning osteosarcoma treatment. The researches included drug delivery systems which allow controlled release and imbue small interfering-/micro- ribonucleic acid.

Methods: Without any language preference, we searched US National Library of Medicine National Institutes of Health, Embase, OVID, Cochrane Library database of clinical trials from 1843 to May 25, 2016 and traced all the references of incorporated documents. The data were evaluated using descriptive statistics and the results are shown as frequency (%).

Results: We haven’t encountered any drug delivery system in which Small interfering ribonucleic acid/ micro ribonucleic acid oligonucleotides were embedded successfully against osteosarcoma. There has been only one research in which hairpin-ribonucleic acid was embedded.

Conclusion: It was considered that drug delivery system enabling controlled oligonucleotide release in the treatment period of osteosarcoma was not projected for the clinical use. However, it cannot be neglected that the mentioned experimental studies with regard to osteosarcoma treatment establish the basis of target therapies. The method in question looks promising regarding effective treatment of osteosarcoma in the future.

Keywords: Controlled release, drug delivery systems, miRNA, osteosarcoma, siRNA, pharmacogenomics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [516 - 522]
Pages: 7
DOI: 10.2174/1389201018666170615083455
Price: $65

Article Metrics

PDF: 18